ABL1 and interstitial lung disease: Knowing that cAbl is a specific target of Im, we decided to evaluate the effectiveness of LIP‐HA44700‐Im in inhibiting the activity of cAbl on pathogenic target cells: BOS and CTD‐ILD LFs.